메뉴 건너뛰기




Volumn 14, Issue 8, 2012, Pages 694-708

The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: A systematic review and meta-analysis

Author keywords

Fasting plasma glucose; Glucagon; Haemoglobin A1c; Hypoglycaemia; Linagliptin; Postprandial glucose; T2DM; Upper respiratory infections

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; LINAGLIPTIN; METFORMIN; PIOGLITAZONE; PLACEBO; SULFONYLUREA;

EID: 84863307036     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2012.01586.x     Document Type: Article
Times cited : (29)

References (34)
  • 1
    • 79960320200 scopus 로고    scopus 로고
    • Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.
    • Tradjenta [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., 2011.
    • (2011) Tradjenta [package insert].
  • 2
    • 79955022470 scopus 로고    scopus 로고
    • The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus.
    • Forst T, Uhlig-Laske B, Ring A, Ritzhaupt A, Graefe-Mody U, Dugi KA. The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2011; 13: 542-550.
    • (2011) Diabetes Obes Metab , vol.13 , pp. 542-550
    • Forst, T.1    Uhlig-Laske, B.2    Ring, A.3    Ritzhaupt, A.4    Graefe-Mody, U.5    Dugi, K.A.6
  • 3
    • 77954798308 scopus 로고    scopus 로고
    • Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    • Sarashina A, Sesoko S, Nakashima M et al. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects. Clin Ther 2010; 32: 1188-1204.
    • (2010) Clin Ther , vol.32 , pp. 1188-1204
    • Sarashina, A.1    Sesoko, S.2    Nakashima, M.3
  • 4
    • 77950197593 scopus 로고    scopus 로고
    • The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans.
    • Blech S, Ludwig-Schwellinger E, Grafe-Mody EU, Withopf B, Wagner K. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos 2010; 38: 667-678.
    • (2010) Drug Metab Dispos , vol.38 , pp. 667-678
    • Blech, S.1    Ludwig-Schwellinger, E.2    Grafe-Mody, E.U.3    Withopf, B.4    Wagner, K.5
  • 5
    • 84878639052 scopus 로고    scopus 로고
    • Efficacy and safety of 3 doses of BI1356 (Linagliptin) in type 2 diabetes patients.
    • Boehringer Ingelheim Pharmaceuticals. In: Bethesda, MD: National Library of Medicine (US), 2000. Available from URL:. Accessed 16 June 2011.
    • Boehringer Ingelheim Pharmaceuticals. Efficacy and safety of 3 doses of BI1356 (Linagliptin) in type 2 diabetes patients. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US), 2000. Available from URL:. Accessed 16 June 2011.
    • ClinicalTrials.gov [Internet].
  • 6
    • 84878656966 scopus 로고    scopus 로고
    • Japanese P III vs voglibose and placebo.
    • Boehringer Ingelheim Pharmaceuticals. In: Bethesda, MD: National Library of Medicine (US), 2000. Available from URL:. Accessed 29 September 2011.
    • Boehringer Ingelheim Pharmaceuticals. Japanese P III vs voglibose and placebo. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US), 2000. Available from URL:. Accessed 29 September 2011.
    • ClinicalTrials.gov [Internet].
  • 7
    • 84878633339 scopus 로고    scopus 로고
    • Safety and efficacy of linagliptin (BI 1356) plus metformin in type 2 diabetes, factorial design.
    • Boehringer Ingelheim Pharmaceuticals. Bethesda, MD: National Library of Medicine (US). 2000. Available from URL:. Accessed 29 September 2011.
    • Boehringer Ingelheim Pharmaceuticals. Safety and efficacy of linagliptin (BI 1356) plus metformin in type 2 diabetes, factorial design. ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). 2000. Available from URL:. Accessed 29 September 2011.
    • ClinicalTrials.gov [Internet].
  • 9
    • 78851472527 scopus 로고    scopus 로고
    • Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial.
    • Del Prato S, Barnett AH, Huisman H, Neubacher D, Woerle HJ, Dugi KA. Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab 2011; 13: 258-267.
    • (2011) Diabetes Obes Metab , vol.13 , pp. 258-267
    • Del Prato, S.1    Barnett, A.H.2    Huisman, H.3    Neubacher, D.4    Woerle, H.J.5    Dugi, K.A.6
  • 10
    • 79953044464 scopus 로고    scopus 로고
    • Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes.
    • Forst T, Uhlig-Laske B, Ring A et al. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes. Diabet Med 2010; 27: 1409-1419.
    • (2010) Diabet Med , vol.27 , pp. 1409-1419
    • Forst, T.1    Uhlig-Laske, B.2    Ring, A.3
  • 11
    • 79953174825 scopus 로고    scopus 로고
    • Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study.
    • Gomis R, Espadero RM, Jones R, Woerle HJ, Dugi KA. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011; 13: 653-661.
    • (2011) Diabetes Obes Metab , vol.13 , pp. 653-661
    • Gomis, R.1    Espadero, R.M.2    Jones, R.3    Woerle, H.J.4    Dugi, K.A.5
  • 12
    • 80053072352 scopus 로고    scopus 로고
    • Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.
    • Owens DR, Swallow R, Dugi KA, Woerle HJ. Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diabet Med 2011; 28: 1352-1361.
    • (2011) Diabet Med , vol.28 , pp. 1352-1361
    • Owens, D.R.1    Swallow, R.2    Dugi, K.A.3    Woerle, H.J.4
  • 13
    • 78649691630 scopus 로고    scopus 로고
    • Safety and efficacy of linagliptin as add-on therapy to met formin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
    • Taskinen MR, Rosenstock J, Tamminen I et al. Safety and efficacy of linagliptin as add-on therapy to met formin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011; 13: 65-74.
    • (2011) Diabetes Obes Metab , vol.13 , pp. 65-74
    • Taskinen, M.R.1    Rosenstock, J.2    Tamminen, I.3
  • 14
    • 57349160286 scopus 로고    scopus 로고
    • Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.
    • Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009; 52: 17-30.
    • (2009) Diabetologia , vol.52 , pp. 17-30
    • Nathan, D.M.1    Buse, J.B.2    Davidson, M.B.3
  • 16
    • 85100415918 scopus 로고    scopus 로고
    • Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2011. Available from URL:. Accessed 20 June 2011.
    • Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2011. Available from URL:. Accessed 20 June 2011.
    • Higgins, J.1    Green, S.2
  • 17
    • 68549101842 scopus 로고    scopus 로고
    • The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.
    • Liberati A, Altman DG, Tetzlaff J et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700.
    • (2009) BMJ , vol.339
    • Liberati, A.1    Altman, D.G.2    Tetzlaff, J.3
  • 18
    • 0036615275 scopus 로고    scopus 로고
    • The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes.
    • Bergman RN, Finegood DT, Kahn SE. The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes. European Journal of Clinical Investigation 2002; 32 (Suppl 3): 35-45.
    • (2002) European Journal of Clinical Investigation , vol.32 , Issue.SUPPL. 3 , pp. 35-45
    • Bergman, R.N.1    Finegood, D.T.2    Kahn, S.E.3
  • 19
    • 84878629649 scopus 로고    scopus 로고
    • Efficacy and safety of linagliptin in patients with type 2 diabetes and poor glycemic control (Abstract). Poster presented at:Clinical Therapeutics/New Technology-Pharmacologic Treatment of Diabetes or its Complications. American Diabetes Association, 71st Scientific Sessions; 24-28 June 2011. San Diego, CA. -
    • Del Prato S, Taskinen M, Owens D et al. Efficacy and safety of linagliptin in patients with type 2 diabetes and poor glycemic control (Abstract). Poster presented at:Clinical Therapeutics/New Technology-Pharmacologic Treatment of Diabetes or its Complications. American Diabetes Association, 71st Scientific Sessions; 24-28 June 2011. San Diego, CA. 1067-p.
    • Del Prato, S.1    Taskinen, M.2    Owens, D.3
  • 20
    • 79956326006 scopus 로고    scopus 로고
    • Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials.
    • Esposito K, Cozzolino D, Bellastella G, et al. Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Obes Metab 2011; 13: 594-603.
    • (2011) Diabetes Obes Metab , vol.13 , pp. 594-603
    • Esposito, K.1    Cozzolino, D.2    Bellastella, G.3
  • 21
    • 84857029848 scopus 로고    scopus 로고
    • Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients.
    • Esposito K, Chiodini P, Bellastella G, Maiorino MI, Giugliano D. Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients. Diabetes Obes Metab 2012; 14: 228-233.
    • (2012) Diabetes Obes Metab , vol.14 , pp. 228-233
    • Esposito, K.1    Chiodini, P.2    Bellastella, G.3    Maiorino, M.I.4    Giugliano, D.5
  • 22
    • 84878654356 scopus 로고    scopus 로고
    • The DPP-4 inhibitor linaglitpin restores β-cell function and survival in human isolated islets (Abstract). Poster presented at: American Diabetes Association, 70th Scientific Sessions; 25-29 June 2010, Orlando, FL 1742-P.
    • Shah P, Schumann DM, Ardestani A, et al. The DPP-4 inhibitor linaglitpin restores β-cell function and survival in human isolated islets (Abstract). Poster presented at: American Diabetes Association, 70th Scientific Sessions; 25-29 June 2010, Orlando, FL 1742-P.
    • Shah, P.1    Schumann, D.M.2    Ardestani, A.3
  • 24
    • 38949128333 scopus 로고    scopus 로고
    • Whitehouse Station, NJ: Merck & Co., Inc.
    • Januvia [package insert]. Whitehouse Station, NJ: Merck & Co., Inc., 2011.
    • (2011) Januvia [package insert].
  • 25
    • 74549198914 scopus 로고    scopus 로고
    • Princeton, NJ: Bristol-Myers Squibb
    • Onglyza [package insert]. Princeton, NJ: Bristol-Myers Squibb, 2011.
    • (2011) Onglyza [package insert].
  • 26
    • 79951701438 scopus 로고    scopus 로고
    • Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase.
    • Willemen MJ, Mantel-Teeuwisse AK, Straus SM, Meyboom RH, Egberts TC, Leufkens HG. Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase. Diabetes Care 2011; 34: 369-374.
    • (2011) Diabetes Care , vol.34 , pp. 369-374
    • Willemen, M.J.1    Mantel-Teeuwisse, A.K.2    Straus, S.M.3    Meyboom, R.H.4    Egberts, T.C.5    Leufkens, H.G.6
  • 27
    • 84878643478 scopus 로고    scopus 로고
    • Linagliptin has similar efficacy to glimepiride but improved cardiovascular safety over 2 years in patients with type 2 diabetes inadequately controlled on metformin (Abstract). Poster presented at:Clinical Therapeutics/New Technology-Pharmacologic Treatment of Diabetes or its Complications. American Diabetes Association, 71st Scientific Sessions; 24-28 June 2011, San Diego, CA. 39-LB.
    • Gallwitz B, Uhlig-Laske B, Bhattacharaya S, Patel S, Woerle HJ. Linagliptin has similar efficacy to glimepiride but improved cardiovascular safety over 2 years in patients with type 2 diabetes inadequately controlled on metformin (Abstract). Poster presented at:Clinical Therapeutics/New Technology-Pharmacologic Treatment of Diabetes or its Complications. American Diabetes Association, 71st Scientific Sessions; 24-28 June 2011, San Diego, CA. 39-LB.
    • Gallwitz, B.1    Uhlig-Laske, B.2    Bhattacharaya, S.3    Patel, S.4    Woerle, H.J.5
  • 28
    • 84878666336 scopus 로고    scopus 로고
    • CV risk with linagliptin in patients with type 2 diabetes: a prespecified, prospective, and adjuicated meta-analysis from a large phase III program (Abstract). Poster presented at:Clinical Therapeutics/New Technology-Pharmacologic Treatment of Diabetes or its Complications. American Diabetes Association, 71st Scientific Sessions; 24-28 June 2011. San Diego, CA. 0030-LB.
    • Johansen OE, Neubacher D, Von Eynatten M, Patel S, Woerle HJ. CV risk with linagliptin in patients with type 2 diabetes: a prespecified, prospective, and adjuicated meta-analysis from a large phase III program (Abstract). Poster presented at:Clinical Therapeutics/New Technology-Pharmacologic Treatment of Diabetes or its Complications. American Diabetes Association, 71st Scientific Sessions; 24-28 June 2011. San Diego, CA. 0030-LB.
    • Johansen, O.E.1    Neubacher, D.2    Von Eynatten, M.3    Patel, S.4    Woerle, H.J.5
  • 29
    • 84878648020 scopus 로고    scopus 로고
    • Dipepidyl peptidase-4 inhibitors and cardiovascular events: a protective effect? (Abstract). Poster presented at: European Association for the Study of Diabetes 2011 Meeting; 16 September 2011; Lisbon, Portugal. 244.
    • Lamanna C, Monami M, Bartoli N, et al. Dipepidyl peptidase-4 inhibitors and cardiovascular events: a protective effect? (Abstract). Poster presented at: European Association for the Study of Diabetes 2011 Meeting; 16 September 2011; Lisbon, Portugal. 244.
    • Lamanna, C.1    Monami, M.2    Bartoli, N.3
  • 30
    • 84878660610 scopus 로고    scopus 로고
    • Rationale and design of the CAROLINA Trial: an active comparator CARdOvascular outcome study of the DPP-4 inhibitor LINAgliptin in patients with type 2 diabetes at high cardiovascular risk (Abstract). Poster presented at:Clinical Therapeutics/New Technology-Pharmacologic Treatment of Diabetes or its Complications. American Diabetes Association, 71st Scientific Sessions; 24-28 June 2011, San Diego, CA. 1103-P.
    • Rosenstock J, Marx N, Kahn SE, et al. Rationale and design of the CAROLINA Trial: an active comparator CARdOvascular outcome study of the DPP-4 inhibitor LINAgliptin in patients with type 2 diabetes at high cardiovascular risk (Abstract). Poster presented at:Clinical Therapeutics/New Technology-Pharmacologic Treatment of Diabetes or its Complications. American Diabetes Association, 71st Scientific Sessions; 24-28 June 2011, San Diego, CA. 1103-P.
    • Rosenstock, J.1    Marx, N.2    Kahn, S.E.3
  • 31
    • 79955728359 scopus 로고    scopus 로고
    • Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials.
    • Monami M, Cremasco F, Lamanna C, Marchionni N, Mannucci E. Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials. Diabetes Metab Res Rev 2011; 27: 362-372.
    • (2011) Diabetes Metab Res Rev , vol.27 , pp. 362-372
    • Monami, M.1    Cremasco, F.2    Lamanna, C.3    Marchionni, N.4    Mannucci, E.5
  • 32
    • 79959559653 scopus 로고    scopus 로고
    • Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.
    • Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011; 141: 150-156.
    • (2011) Gastroenterology , vol.141 , pp. 150-156
    • Elashoff, M.1    Matveyenko, A.V.2    Gier, B.3    Elashoff, R.4    Butler, P.C.5
  • 33
    • 0043198131 scopus 로고    scopus 로고
    • Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?
    • Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA 2003; 290: 921-928.
    • (2003) JAMA , vol.290 , pp. 921-928
    • Als-Nielsen, B.1    Chen, W.2    Gluud, C.3    Kjaergard, L.L.4
  • 34
    • 0038439242 scopus 로고    scopus 로고
    • Pharmaceutical industry sponsorship and research outcome and quality: systematic review.
    • Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003; 326: 1167-1170.
    • (2003) BMJ , vol.326 , pp. 1167-1170
    • Lexchin, J.1    Bero, L.A.2    Djulbegovic, B.3    Clark, O.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.